Loading…
CollPlant Biotechnologies Ltd. is projected to decline to $0.3855 by 2027, a -6% move from its current price of $0.4101. CLGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.3913 | $0.4102 | $0.4301 | +0.04% |
| May 30 | $0.3839 | $0.4104 | $0.4387 | +0.07% |
| May 31 | $0.3783 | $0.4105 | $0.4455 | +0.11% |
| Jun 1 | $0.3737 | $0.4107 | $0.4514 | +0.15% |
| Jun 2 | $0.3697 | $0.4108 | $0.4566 | +0.18% |
| Jun 3 | $0.3661 | $0.411 | $0.4614 | +0.22% |
| Jun 4 | $0.3629 | $0.4111 | $0.4658 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3629 | $0.4111 | $0.4658 | +0.26% |
| Week 2 | $0.3455 | $0.4122 | $0.4918 | +0.51% |
| Week 3 | $0.3329 | $0.4133 | $0.513 | +0.77% |
| Week 4 | $0.3228 | $0.4143 | $0.5318 | +1.03% |
| Week 5 | $0.3142 | $0.4154 | $0.5492 | +1.29% |
| Week 6 | $0.3067 | $0.4164 | $0.5654 | +1.55% |
| Week 7 | $0.30 | $0.4175 | $0.5809 | +1.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CollPlant Biotechnologies Ltd. is a healthcare company focused on regenerative and aesthetic medicine, with a specialization in three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics across the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant human collagen (rhCollagen) produced using its proprietary technology, and the company offers regenerative dermal and soft tissue fillers, 3D-bioprinted regenerative breast implants, and rhCollagen-based bioinks for regenerative medicine applications, such as Collink.3D 50L, Collink.3D 90, and Collink.3D 50.
CollPlant also markets Collage, a combinant human Collagen type I solution. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. CollPlant Biotechnologies Ltd.
was founded in 2004 and is headquartered in Rehovot, Israel.
CollPlant Biotechnologies Ltd. (CLGN) is a healthcare company focused on regenerative and aesthetic medicine. The stock currently trades at $0.4264 per share and has a market cap of $6.15M, ranking 5289 by market capitalization.
The near-term price picture is underpinned by neutral technicals, with a 30-day range and key support/resistance levels guiding activity. The overall price outlook is informed by a multi-year forecast that shows periods of stability near the current price followed by upside potential in later years.
A major floor 35.8% below — a decisive break under it would weaken the trend.
The nearest floor, 22.0% below — buyers have tended to step in here.
The nearest ceiling, 9.7% above — a clean break opens room to run.
A major ceiling 374.5% above — clearing it would confirm fresh momentum.
Key CLGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4242 | Sell | $0.4189 | Sell |
| MA 10 | $0.4255 | Sell | $0.4195 | Sell |
| MA 20 | $0.4123 | Sell | $0.4181 | Sell |
| MA 50 | $0.4498 | Sell | $0.5032 | Sell |
| MA 100 | $0.7713 | Sell | $0.7848 | Sell |
| MA 200 | $1.52 | Sell | $1.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.57 | Neutral |
| Stoch RSI (14) | 27.08 | Neutral |
| CCI (20) | -10.90 | Neutral |
| Williams %R (14) | -70.18 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 1.99 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 29.82 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 42.31 | Neutral |
| Momentum (10) | 0.00 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 0.42 | Sell |
| ADX (14) | 11.46 | Neutral |
| ATR (14) | 0.02 | Info |
Technical picture over the last 30 days is NEUTRAL, with RSI14 at 50 and moving averages near pivotal levels. The 50-day simple moving average sits at $0.4572, while the 200-day simple moving average stands at $1.54. The stock shows support at $0.293 and resistance at $0.45, signaling a cautious stance near current levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.293 | $0.4101 | $0.5432 | 0% | Neutral | |
| $0.2842 | $0.3855 | $0.5643 | -6% | Neutral | |
| $0.2718 | $0.3881 | $0.6007 | -5% | Neutral | |
| $0.238 | $0.355 | $0.5737 | -13% | Neutral | |
| $0.2967 | $0.4604 | $0.7714 | +12% | Neutral | |
| $0.3246 | $0.5226 | $0.9035 | +27% | Bullish | |
| $0.3102 | $0.5173 | $0.9197 | +26% | Bullish | |
| $0.3348 | $0.5773 | $1.05 | +41% | Bullish | |
| $0.2709 | $0.4825 | $0.90 | +18% | Neutral | |
| $0.2363 | $0.4343 | $0.8274 | +6% | Neutral | |
| $0.3255 | $0.6955 | $1.45 | +70% | Bullish | |
| $0.4251 | $0.9446 | $2.17 | +130% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.293 | $0.4101 | $0.4876 | +0.00% |
| June 2026 | $0.3605 | $0.4302 | $0.5304 | +4.90% |
| July 2026 | $0.3501 | $0.424 | $0.5348 | -1.44% |
| August 2026 | $0.335 | $0.4104 | $0.5266 | -3.20% |
| September 2026 | $0.3451 | $0.4269 | $0.5555 | +4.02% |
| October 2026 | $0.35 | $0.4369 | $0.5756 | +2.33% |
| November 2026 | $0.3286 | $0.4135 | $0.5508 | -5.35% |
| December 2026 | $0.3184 | $0.4037 | $0.5432 | -2.37% |
Click any year to see its month-by-month CLGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CLGN is projected to trade between $0.293 and $0.5432, averaging $0.4101 — a potential gain of 0% from today's $0.4101. A consolidation phase looks the most probable path here.
CollPlant Biotechnologies Ltd.'s 2027 outlook centres on $0.3855, within a $0.2842 to $0.5643 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. Price action looks broadly range-bound.
By 2028, CLGN could reach as high as $0.6007, with a base case around $0.3881 and support toward $0.2718 — roughly -5% from $0.4101. A consolidation phase looks the most probable path here.
Expect CLGN to range from $0.238 to $0.5737 through 2029. The $0.355 average target implies a -13% move from current prices. That is -9% versus the projected 2028 average. Price action looks broadly range-bound.
The CLGN price prediction for 2030 points to an average of $0.4604 (low $0.2967, high $0.7714) — a potential gain of +12% on today's $0.4101. A consolidation phase looks the most probable path here.
In 2031, CLGN is projected to trade between $0.3246 and $0.9035, averaging $0.5226 — a potential gain of +27% from today's $0.4101. That is up +14% on the projected 2030 average. Momentum favours further upside here.
CollPlant Biotechnologies Ltd.'s 2032 outlook centres on $0.5173, within a $0.3102 to $0.9197 range. That is -1% versus the projected 2031 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CLGN could reach as high as $1.05, with a base case around $0.5773 and support toward $0.3348 — roughly +41% from $0.4101. Momentum favours further upside here.
Expect CLGN to range from $0.2709 to $0.90 through 2034. The $0.4825 average target implies a +18% move from current prices. That is -16% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The CLGN price prediction for 2035 points to an average of $0.4343 (low $0.2363, high $0.8274) — a potential gain of +6% on today's $0.4101. Price action looks broadly range-bound.
In 2040, CLGN is projected to trade between $0.3255 and $1.45, averaging $0.6955 — a potential gain of +70% from today's $0.4101. That is up +60% on the projected 2035 average. Buyers look set to stay in control over this stretch.
CollPlant Biotechnologies Ltd.'s 2050 outlook centres on $0.9446, within a $0.4251 to $2.17 range. That is up +36% on the projected 2040 average. That marks a +130% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CLGN today (≈ 2,438.429651 CLGN) could be worth
$2,303.4
+$1,303.4 (+130%) by 2050 · US Dollar
Based on the average projected CLGN price of $0.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLGNwould be worth at today's price.
$1,000 invested in CLGN on May 27, 2025 (≈ 518.134729 CLGN) would be worth
$212.49
-$787.51 (-78.8%) today · 0.21× · US Dollar
Based on a CLGN entry price of $1.93 vs. today's $0.4101.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.45 | $911.33 | -8.9% |
| 1 month ago | $0.41 | $1,000.24 | +0.0% |
| 3 months ago | $0.567 | $723.28 | -27.7% |
| 6 months ago | $2.19 | $187.43 | -81.3% |
| 1 year ago | $1.93 | $212.49 | -78.8% |
| All time (5.0y) ago | $17.1 | $23.98 | -97.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLGN forecast.
Our base-case forecast reaches $0.82 around 2050.
Implied market cap at $0.82: $11.82M
Longer-run forecasts show a range of outcomes. In 2030 the avg price is $0.4784 with a min of $0.3018 and a max of $0.8165, reflecting an ROI of 12.2 and a NEUTRAL stance. The years 2031 and 2032 are bullish, with 2031 min $0.3297, avg $0.5439, max $0.959 and ROI 27.6; 2032 min $0.3177, avg $0.5445, max $0.9881 and ROI 27.7, both with a BULLISH posture.
In 2033 the min is $0.3392, avg $0.6029, max $1.12 and ROI 41.4 with a BULLISH sentiment. 2034 and 2035 show more modest gains (min $0.2675, avg $0.4927, max $0.9397; ROI 15.6; NEUTRAL) and (min $0.2351, avg $0.4481, max $0.8737; ROI 5.1; NEUTRAL). The longer-horizon years 2040 and 2050 project strong upside, with 2040 min $0.3229, avg $0.7175, max $1.53 and ROI 68.3 (BULLISH), and 2050 min $0.4406, avg $0.979, max $2.25 and ROI 129.6 (BULLISH).
There are years with negative ROI in 2027 (-6.5), 2028 (-6.6), and 2029 (-13.8), illustrating that these are estimates and not guarantees. Overall, the forecast depicts upside potential in the long run alongside near-term uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $0.4784 with min $0.3018 and max $0.8165, and ROI 12.2; sentiment is NEUTRAL.
The near term shows a neutral stance around the current price with some years of negative ROI (2027-2029), while the longer term includes bullish years (2031-2033) and strong upside in 2040 and 2050. These are estimates, not guarantees.
Yes. The forecast shows a max of $1.12 in 2033 and a later max of $1.53 in 2040, with a further max of $2.25 in 2050.
For 2040, the forecast is min $0.3229, avg $0.7175, max $1.53, ROI 68.3, sentiment BULLISH.
For 2050, the forecast is min $0.4406, avg $0.979, max $2.25, ROI 129.6, sentiment BULLISH.
CollPlant Biotechnologies Ltd. Community Discussion
0Share your CollPlant Biotechnologies Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.